Biogen's lecanemab receives FDA Breakthrough Therapy Designation in the United States
Show original
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
Glonghui, January 28｜Biogen's Litifilimab has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the treatment of cutaneous lupus erythematosus, a disease that currently has no targeted therapies.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now！
You may also like
AiCoin | April 26 Snapshot: Large ETF Inflows, Quantum Attack Threat, Legislative Warnings
AIcoin•2026/04/26 00:02
Key Overnight Developments on April 26
金色财经•2026/04/25 23:35
Trending news
MoreCrypto prices
More
Bitcoin
BTC
$77,528.87
+0.10%
Ethereum
ETH
$2,317.3
+0.16%
Tether USDt
USDT
$1
-0.01%
XRP
XRP
$1.42
-0.71%
BNB
BNB
$628.19
-1.24%
USDC
USDC
$0.9998
-0.00%
Solana
SOL
$86.13
-0.04%
TRON
TRX
$0.3242
+0.19%
Dogecoin
DOGE
$0.09796
-0.37%
Hyperliquid
HYPE
$41.46
+0.80%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now